Nifty
Sensex
:
:
11745.30
40043.38
-144.10 (-1.21%)
-478.72 (-1.18%)

Pharmaceuticals & Drugs - Global

Rating :
81/99  (View)

BSE: 533573 | NSE: APLLTD

959.10
-1.75 (-0.18%)
28-Oct-2020 | 1:34PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  960.85
  •  965.75
  •  951.00
  •  960.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  106391
  •  1020.40
  •  1128.90
  •  434.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 18,887.75
  • 17.74
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,554.50
  • 1.04%
  • 4.12

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.77%
  • 0.48%
  • 11.67%
  • FII
  • DII
  • Others
  • 7.03%
  • 9.33%
  • 1.72%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.38
  • 7.79
  • 13.74

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 23.85
  • 3.85
  • 14.56

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.52
  • 2.85
  • 25.36

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.25
  • 19.82
  • 19.61

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.18
  • 5.28
  • 4.29

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.98
  • 14.07
  • 13.99

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
1,457
1,241
17%
1,341
949
41%
1,207
927
30%
1,209
1,018
19%
Expenses
1,014
895
13%
934
724
29%
879
749
17%
884
776
14%
EBITDA
443
346
28%
407
225
81%
328
178
84%
325
242
34%
EBIDTM
30%
28%
30%
24%
14%
19%
27%
24%
Other Income
3
0
794%
0
3
-90%
1
3
-74%
0
4
-88%
Interest
4
7
-37%
7
5
34%
8
5
53%
7
6
24%
Depreciation
44
36
22%
42
35
17%
44
30
47%
42
29
44%
PBT
398
303
32%
360
155
132%
266
146
81%
276
211
31%
Tax
73
52
39%
67
36
86%
62
15
317%
49
40
22%
PAT
325
250
30%
293
119
146%
204
131
55%
228
171
33%
PATM
22%
20%
22%
13%
7%
14%
19%
17%
EPS
16.55
12.73
30%
14.89
6.06
146%
10.35
6.69
55%
11.58
8.69
33%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
5,214
4,606
3,935
3,130
3,135
3,166
2,056
1,863
1,520
1,465
1,202
Net Sales Growth
26%
17%
26%
0%
-1%
54%
10%
23%
4%
22%
 
Cost Of Goods Sold
5,592
1,039
993
886
888
824
640
627
610
637
534
Gross Profit
-378
3,566
2,942
2,245
2,247
2,342
1,416
1,236
911
828
668
GP Margin
-7%
77%
75%
72%
72%
74%
69%
66%
60%
56%
56%
Total Expenditure
3,711
3,392
3,079
2,515
2,520
2,161
1,661
1,506
1,272
1,250
1,059
Power & Fuel Cost
-
102
89
70
64
59
43
32
27
30
25
% Of Sales
-
2%
2%
2%
2%
2%
2%
2%
2%
2%
2%
Employee Cost
-
906
747
623
559
473
307
247
194
168
149
% Of Sales
-
20%
19%
20%
18%
15%
15%
13%
13%
12%
12%
Manufacturing Exp.
-
368
269
245
290
210
263
272
192
184
145
% Of Sales
-
8%
7%
8%
9%
7%
13%
15%
13%
13%
12%
General & Admin Exp.
-
340
341
283
300
233
146
118
88
80
63
% Of Sales
-
7%
9%
9%
10%
7%
7%
6%
6%
5%
5%
Selling & Distn. Exp.
-
531
590
380
393
245
245
194
155
130
114
% Of Sales
-
12%
15%
12%
13%
8%
12%
10%
10%
9%
9%
Miscellaneous Exp.
-
104
51
28
27
117
17
16
7
20
114
% Of Sales
-
2%
1%
1%
1%
4%
1%
1%
0%
1%
2%
EBITDA
1,503
1,214
856
615
615
1,005
395
357
249
216
143
EBITDA Margin
29%
26%
22%
20%
20%
32%
19%
19%
16%
15%
12%
Other Income
5
14
27
35
3
9
12
4
17
16
21
Interest
26
27
18
3
5
5
4
10
24
38
28
Depreciation
171
157
115
105
83
72
44
40
35
34
30
PBT
1,300
1,043
749
541
529
936
359
311
206
161
107
Tax
250
199
157
120
122
216
76
75
41
31
21
Tax Rate
19%
20%
21%
22%
23%
23%
21%
24%
20%
19%
20%
PAT
1,049
829
594
421
407
720
283
236
165
130
85
PAT before Minority Interest
1,064
801
593
421
407
720
283
236
165
130
85
Minority Interest
15
28
1
0
0
0
0
0
0
0
0
PAT Margin
20%
18%
15%
13%
13%
23%
14%
13%
11%
9%
7%
PAT Growth
56%
40%
41%
3%
-43%
155%
20%
43%
27%
52%
 
EPS
53.38
42.15
30.20
21.40
20.70
36.63
14.38
11.98
8.41
6.62
4.34

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
3,219
2,719
2,220
1,902
1,597
885
676
503
395
297
Share Capital
38
38
38
38
38
38
38
38
38
11
Total Reserves
3,182
2,681
2,182
1,865
1,560
847
638
465
357
259
Non-Current Liabilities
1,047
570
576
94
84
72
94
103
122
151
Secured Loans
0
0
0
0
0
19
42
60
76
90
Unsecured Loans
887
499
500
0
0
0
10
11
19
39
Long Term Provisions
75
52
41
57
28
9
7
6
5
5
Current Liabilities
1,752
1,490
1,144
693
747
684
603
529
583
413
Trade Payables
626
644
759
501
566
325
288
240
209
139
Other Current Liabilities
227
380
143
81
52
45
61
69
152
85
Short Term Borrowings
860
429
208
89
114
220
25
70
138
146
Short Term Provisions
38
36
34
22
16
95
228
149
84
44
Total Liabilities
5,989
4,778
3,941
2,689
2,429
1,641
1,372
1,135
1,100
861
Net Block
1,552
1,158
993
799
708
547
397
344
268
272
Gross Block
2,132
1,523
1,242
950
1,094
861
665
572
463
434
Accumulated Depreciation
527
364
249
151
386
314
268
228
195
162
Non Current Assets
3,526
2,820
2,116
1,317
917
750
516
416
364
308
Capital Work in Progress
1,846
1,551
1,010
396
93
83
21
32
58
26
Non Current Investment
18
49
42
50
53
2
3
3
3
3
Long Term Loans & Adv.
111
62
71
71
30
118
95
36
35
7
Other Non Current Assets
0
0
0
0
33
0
0
0
0
0
Current Assets
2,463
1,958
1,825
1,372
1,511
891
857
719
736
553
Current Investments
0
0
0
0
0
0
0
0
0
0
Inventories
1,188
967
734
633
570
383
311
267
259
219
Sundry Debtors
865
489
526
339
350
361
273
233
199
202
Cash & Bank
81
206
90
160
451
27
24
16
47
6
Other Current Assets
330
18
27
8
140
120
248
203
231
125
Short Term Loans & Adv.
302
278
447
234
133
120
248
203
231
125
Net Current Assets
711
468
680
680
764
207
254
191
153
139
Total Assets
5,989
4,778
3,941
2,689
2,429
1,641
1,372
1,135
1,100
861

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
449
812
312
329
948
172
240
265
142
95
PBT
1,000
749
541
529
936
359
311
206
161
107
Adjustment
278
118
87
83
70
45
70
53
75
55
Changes in Working Capital
-593
112
-181
-166
139
-162
-72
44
-62
-49
Cash after chg. in Working capital
685
978
448
447
1,145
241
309
304
174
113
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-236
-166
-135
-118
-197
-69
-69
-39
-33
-18
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-732
-756
-884
-486
-307
-256
-81
-67
-56
-57
Net Fixed Assets
-790
-630
-607
-122
-289
-200
-81
-84
-61
Net Investments
-327
-216
-196
-66
-4
0
-30
0
0
Others
385
91
-82
-299
-14
-55
30
17
5
Cash from Financing Activity
155
59
503
-129
-224
87
-151
-229
-45
-47
Net Cash Inflow / Outflow
-128
115
-69
-286
417
3
8
-31
41
-9
Opening Cash & Equivalents
199
84
153
439
23
24
16
47
6
15
Closing Cash & Equivalent
72
199
84
153
439
27
24
16
47
6

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
171
144
118
101
85
47
36
27
21
49
ROA
15%
14%
13%
16%
35%
19%
19%
15%
13%
10%
ROE
27%
24%
20%
23%
58%
36%
40%
37%
39%
32%
ROCE
23%
23%
22%
29%
66%
38%
44%
32%
29%
22%
Fixed Asset Turnover
2.52
2.85
2.86
3.07
3.24
2.71
3.02
2.95
3.28
2.79
Receivable days
54
47
50
40
41
56
49
52
50
61
Inventory Days
85
79
80
70
55
61
56
63
59
66
Payable days
70
88
98
84
84
70
66
69
51
51
Cash Conversion Cycle
69
38
32
26
12
47
39
45
58
76
Total Debt/Equity
0.54
0.42
0.32
0.05
0.07
0.30
0.16
0.37
0.89
1.21
Interest Cover
38
42
160
102
173
95
31
10
5
5

News Update


  • Alembic Pharmaceuticals gets USFDA’s nod for Timolol Maleate Ophthalmic Gel Forming Solution
    26th Oct 2020, 09:44 AM

    Alembic has a cumulative total of 134 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals reports 35% rise in Q2 consolidated net profit
    23rd Oct 2020, 11:41 AM

    Total income of the company increased by 17.65% at Rs 1460.32 crore for Q2FY21

    Read More
  • Alembic Pharmaceuticals’ JV gets final approval for Tavaborole Topical Solution
    22nd Oct 2020, 11:38 AM

    Tavaborole Topical Solution, 5% has an estimated market size of $82 million for twelve months ending June 2020

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final approval for Fenofibrate Capsules
    21st Oct 2020, 11:49 AM

    Alembic Pharmaceuticals has a cumulative total of 133 ANDA

    Read More
  • Alembic Pharmaceuticals gets USFDA approval for Amantadine Hydrochloride Tablets
    16th Oct 2020, 12:27 PM

    Amantadine Hydrochloride Tablets are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions

    Read More
  • Alembic Pharmaceuticals’ Rhizen inks pact with Curon Biopharmaceutical
    13th Oct 2020, 09:50 AM

    The agreement is for development and commercialization of Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

    Read More
  • Alembic Pharmaceuticals’ arm gets tentative approval for Treprostinil Injection
    7th Sep 2020, 11:45 AM

    The company now has a total of 131 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals gets USFDA’s tentative approval for Empagliflozin, Linagliptin Tablets
    27th Aug 2020, 10:52 AM

    Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg have an estimated market size of $ 244 million for twelve months ending June 2020

    Read More
  • Alembic Pharmaceuticals’ JV gets USFDA’s final nod for Desonide Lotion
    25th Aug 2020, 14:51 PM

    The company has a cumulative total of 129 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals’ JV gets USFDA’s tentative approval for tavaborole topical solution
    13th Aug 2020, 13:56 PM

    The company has a cumulative total of 128 ANDA approvals (112 final approvals and 16 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals gets nod to raise up to Rs 1,000 crore via QIP
    27th Jul 2020, 14:22 PM

    The board at its meeting has accorded its approval to raise up to Rs 1,000 crore through a QIP issue of equity shares

    Read More
  • Alembic Pharmaceuticals reports 2- fold jump in Q1 consolidated net profit
    23rd Jul 2020, 10:52 AM

    Total income of the company increased by 40.90% at Rs 1341.64 crore for Q1FY21

    Read More
  • Alembic Pharma - Quarterly Results
    22nd Jul 2020, 13:44 PM

    Read More
  • Alembic Pharma gets tentative approval for Empagliflozin, Metformin Hydrochloride Tablets
    20th Jul 2020, 10:26 AM

    The company now has a total of 126 ANDA approvals from USFDA

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.